— So far this year alone, 25 TULSA-related scientific research presentations have been delivered at major medical meetings around the world — — Of those, eight (8) presentations were from leading ...

SSM Health Saint Louis University Hospital recently performed the first transurethral ultrasound ablation (TULSA) procedure in Missouri as well as the larger Midwest region. It’s a minimally-invasive ...

TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...

Profound Medical (PROF) announced the unveiling of its third TULSA-AI software module, UA Alignment Assistant, in addition to six presentations featuring the Transurethral Ultrasound Ablation ...

– TULSA had no blood loss and no overnight stay, along with reduced post-procedure pain, and more rapid recovery to baseline activities and overall health – The positive perioperative results were ...

Aggressive. When he heard that word, Ken Richter knew he needed to act quickly. The Magnolia resident received his first cancer diagnosis in 2015 after a colonoscopy revealed an abnormal mass on his ...

Profound Medical (PROF) announced the upcoming launch of its TULSA-AI Volume Reduction module for optimizing the treatment of patients with benign prostatic hyperplasia, or enlarged prostate, at the ...

TORONTO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...

February is American Heart Month. Many people in Oklahoma have congestive heart failure and a lot of them end up in the hospital. In fact, doctors said it’s the leading cause of hospital admission in ...

— Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — “The various presentations made at AUA and other major ...

— Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Profound ...